Related Experiment Video
Updated: Jan 5, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Circulating miR-106a may Function as Potential Biomarkers in Patients with Coronary Artery Disease
Insights
Plasma miR-106a levels are elevated in coronary artery disease (CAD) patients, indicating its potential as a biomarker for early diagnosis and assessing disease severity. This finding aids in understanding CAD progression.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Molecular Biology
Background:
- Coronary artery disease (CAD) is a leading cause of cardiovascular mortality and sudden cardiac death.
- Early diagnosis and identification of novel biomarkers are crucial for managing CAD.
- This study investigates the role of microRNA-106a (miR-106a) as a potential biomarker in CAD.
Purpose of the Study:
- To determine the clinical significance of plasma miR-106a levels in patients with CAD.
- To assess the correlation between plasma miR-106a levels and CAD severity (SYNTAX score).
- To explore the relationship between miR-106a, oxidized low-density lipoprotein (ox-LDL), and 25-hydroxyvitamin D3 (25(OH)D3) in CAD patients.
Main Methods:
- Plasma samples from 92 CAD patients and 92 healthy controls were analyzed.
- Quantitative real-time PCR (RT-qPCR) was used to measure miR-106a expression levels.
- Associations with SYNTAX score, ox-LDL, and 25(OH)D3 levels were statistically analyzed.
Main Results:
- miR-106a was significantly upregulated in the plasma of CAD patients compared to controls.
- Receiver operating characteristic (ROC) curve analysis indicated miR-106a as a sensitive diagnostic biomarker for CAD (AUC = 0.8189).
- Plasma miR-106a levels positively correlated with SYNTAX score, ox-LDL levels, and negatively correlated with 25(OH)D3 levels.
Conclusions:
- miR-106a is upregulated in CAD and shows potential as a biomarker for early diagnosis.
- Plasma miR-106a levels may aid in evaluating the clinical outcomes and severity of CAD.
- The findings suggest a link between miR-106a, lipid metabolism, and vitamin D status in CAD pathogenesis.
Background:
Coronary artery disease (CAD) is a common cardiovascular disorder, and CAD is also the main cause of sudden cardiac death. Thus, identification of novel biomarkers for the early diagnosis and treatment of CAD is urgently needed. This study aims to explore the clinical significance of the plasma level of miR-106a in CAD.
Methods:
A total of 92 patients were enrolled in the present study, and 92 healthy volunteers were enrolled as the control. The plasma samples of the participants were collected, and the expression levels of miR-106a in the plasma of the patients and healthy controls were compared by RT-qPCR methods. Moreover, the association between the plasma level of miR-106a and the SYNTAX scoring (SS) of the patients were analyzed. Finally, the serum levels of 25 (OH) D3 and oxidized low-density lipoprotein (ox-LDL) between the patients and healthy controls were compared, and the correlation between the plasma level of miR-106a and the serum level of 25 (OH) D3 and ox-LDL in patients with CAD were analyzed.
Results:
miR-106a was significantly up-regulated in plasma of patients with CAD. Results of receiver operation characteristics (ROC) curve showed that the plasma level of miR-106a is a sensitive biomarker for the diagnosis of CAD (AUC = 0.8189, 95% CI = 0.7578 to 0.8799). Furthermore, the plasma level of miR-106a was positively correlated with the SS of the patients. Finally, ox-LDL was markedly increased and 25 (OH) D3 was significantly de-creased in the serum of patients with CAD. The plasma level of miR-106a was positively correlated with the level of ox-LDL and negatively correlated with the level of 25 (OH) D3 in patients with CAD.
Conclusions:
miR-106a was up-regulated in CAD, and miR-106a may serve as a potential biomarker for the early diagnosis and evaluation of clinical outcomes of CAD.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology